Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Replimune Group Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
REPL
Nasdaq
8731
https://www.replimune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Replimune Group Inc
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
- Apr 7th, 2024 9:00 pm
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 4th, 2024 12:00 pm
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
- Mar 26th, 2024 11:30 am
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
- Mar 11th, 2024 1:55 pm
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
- Mar 8th, 2024 5:00 pm
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
- Mar 6th, 2024 1:00 pm
Replimune to Present at Three Upcoming Investor Conferences
- Mar 5th, 2024 1:00 pm
12 Best Medical Stocks to Buy Under $10
- Feb 27th, 2024 8:30 am
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
- Feb 23rd, 2024 2:55 pm
Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway
- Feb 8th, 2024 1:42 pm
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
- Feb 8th, 2024 1:00 pm
15 Small-Cap Stocks with High Potential
- Jan 22nd, 2024 3:54 pm
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
- Jan 16th, 2024 8:59 am
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 28th, 2023 1:00 pm
An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued
- Dec 7th, 2023 10:40 am
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
- Dec 5th, 2023 12:00 pm
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
- Nov 8th, 2023 2:10 pm
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
- Nov 7th, 2023 1:00 pm
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Nov 3rd, 2023 11:30 pm
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
- Sep 19th, 2023 12:00 pm
Scroll